PharmRep Direct from the editors of Pharmaceutical Representative

July 26, 2010 Issue 41 Vol. 8	www.pharmrep.com
Contact Editor: Reid Paul

Advisory Panel Rejects Avastin For Breast Cancer Treatment
Following the release of post-approval clinical studies, an FDA advisory committee determined that Roche’s cancer drug Avastin should not be used by patients being treated for metastatic breast cancer.
ť MORE

Pfizer Suspends More Tanezunab Trials
Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications.
ť MORE

Weight-Loss Drug Qnexa Loses in FDA Committee Ruling
Vivus’ Qnexa may help in weight loss, but it also now risks losing its place in the market following FDA’s Advisory Committee’s ruling July 15.
ť MORE

Are Your Samples Safe?
Samples are an essential but overlooked part of the rep’s work, but sometimes don’t get the attention they deserve. In Pharm Rep takes a look at industry best practices and guidelines to determine how to ensure samples remain safe and secure
ť MORE

Certified Letter
The Medical Representative Certification Commission is embarking on a new mission to rebuild rep’s trust in the eyes of physicians. Pharm Rep examines MRCC’s progress and asks, will it work?
ť MORE

Media Spend Trends
Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?
ť MORE

Physicians Stay Put
A new study indicates that doctors are no longer switching offices—largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.
ť MORE

Lessons from Novartis Discrimination Suit

J&J Recall Timeline

New Head Named for PhrMA

Follow Pharm Rep on Twitter

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.